Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors.
Ali Y, Lin Y, Gharibo MM, Gounder MK, Stein MN, Lagattuta TF, Egorin MJ, Rubin EH, Poplin EA. The Cancer Institute of New Jersey, University of Medicine & Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903, USA.

Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma.
Porta C, Mutti L, Tassi G. PMID: 16636799 [PubMed - indexed for MEDLINE]

Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial.
Mathy A, Baas P, Dalesio O, van Zandwijk N. Biometrics Department, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. a.mathy@nki.nl

Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.
Jackman DM, Kindler HL, Yeap BY, Fidias P, Salgia R, Lucca J, Morse LK, Ostler PA, Johnson BE, Jänne PA. Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.

Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, Nagle RB, Klein-Szanto AJ, Testa JR, Altomare DA, Borden EC. University of Arizona Cancer Center, Tucson, AZ, USA.